BARBARA JULIA LOPEZ MD
Prescription History 1255949244
General Practice in Aguada, PR

NPI Status: Active since July 16, 2020

Contact Information

EDIF. CENTERPLEX
CARR #2 KM 133.5 SUITE 307
AGUADA, PR
ZIP 00602
Phone: (787) 658-0200

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for BARBARA JULIA LOPEZ MD, an active General Practice specialist practicing in Aguada, PR. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 82 documented patient claims. Among these therapy options, the most frequently utilized medication is Dexamethasone, which accounts for 23 claims alone.

Medication Index

No matching medications currently found on file.

Clindamycin Hcl

Generic Formulation: Clindamycin HclSpecialty: General Practice
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 111
PR State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills34.5
Peer Average Days Supply233
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 64.7% less volume than the regional standard for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $89.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.48

State Avg Cost Per Claim

$9.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.

Therapeutic Applications

Clindamycin is used to treat a wide variety of bacterial infections. It is an antibiotic that works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for virus infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: General Practice
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 117
PR State Average Benchmarks
Peer Average Claims52.0
Peer Average 30-Day Fills52.5
Peer Average Days Supply443
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.8% less volume than the regional standard for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $134.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.86

State Avg Cost Per Claim

$15.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Famotidine

Generic Formulation: FamotidineSpecialty: General Practice
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 117
PR State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.0
Peer Average Days Supply377
Conservative Utilization

This provider writes prescriptions for this formulation 29.4% less frequently than the standard regional baseline metric for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $113.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.47

State Avg Cost Per Claim

$4.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

Therapeutic Applications

Famotidine is used to treat ulcers of the stomach and intestines and to prevent intestinal ulcers from coming back after they have healed. This medication is also used to treat certain stomach and throat (esophagus) problems (such as erosive esophagitis, gastroesophageal reflux disease-GERD, Zollinger-Ellison syndrome). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as cough that doesn't go away, stomach pain, heartburn, and difficulty swallowing. Famotidine belongs to a class of drugs known as H2 blockers. This medication is also available without a prescription. It is used to prevent and treat heartburn and other symptoms caused by too much acid in the stomach (acid indigestion). If you are taking this medication for self-treatment, it is important to read the manufacturer's package instructions carefully so you know when to consult your doctor or pharmacist.

Nabumetone

Generic Formulation: NabumetoneSpecialty: General Practice
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 190
PR State Average Benchmarks
Peer Average Claims63.0
Peer Average 30-Day Fills66.2
Peer Average Days Supply1,506
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.3% less volume than the regional standard for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $142.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.12

State Avg Cost Per Claim

$14.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.

Therapeutic Applications

Nabumetone is used to reduce pain, swelling, and joint stiffness from arthritis. This medication is known as a nonsteroidal anti-inflammatory drug (NSAID). If you are treating a chronic condition such as arthritis, ask your doctor about non-drug treatments and/or using other medications to treat your pain. See also Warning section.

Paxlovid (Eua)

Generic Formulation: Nirmatrelvir/RitonavirSpecialty: General Practice
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 75
PR State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.4
Peer Average Days Supply113
Conservative Utilization

This provider writes prescriptions for this formulation 31.8% less frequently than the standard regional baseline metric for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $25.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$1.70

State Avg Cost Per Claim

$2.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

The combination of nirmatrelvir tablets and ritonavir tablets is a product that the FDA is allowing to be given for emergency use to treat COVID-19. The product is also approved to be used in Canada to treat COVID-19. It is used by people who have recently tested positive for coronavirus, have had mild to moderate symptoms for no more than 5 days and are not hospitalized. To receive this product you must also be at high risk for COVID-19 complications due to older age, obesity, or ongoing medical conditions (such as lung or heart disease or diabetes, among others). Talk to your doctor about the risks and benefits of treatment with nirmatrelvir and ritonavir. Nirmatrelvir is a SARS-CoV-2 main protease inhibitor. It works by preventing the growth of the virus that causes COVID-19. Ritonavir increases (boosts) the levels of nirmatrelvir. This helps nirmatrelvir work better. More information about nirmatrelvir and ritonavir is available from the FDA Fact Sheet for Patients, Parents, and Caregivers for Emergency Use and from the Health Canada Patient Medication Information sheet. There is limited information about how safe and effective the combination of nirmatrelvir and ritonavir is for treating COVID-19. Study results show that nirmatrelvir and ritonavir may help people who have recently tested positive for coronavirus stay out of the hospital. This product is not for use by people who are hospitalized due to COVID-19. The information in this document reflects emerging data, which is evolving and subject to reassessment. Users should be aware of these considerations in their review of nirmatrelvir and ritonavir, and it is always the responsibility of treating practitioners to exercise independent judgement in making care decisions.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like BARBARA JULIA LOPEZ MD provides transparency into local medical care patterns within Aguada, PR.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **General Practice** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.